Scopus Biopharma Stock Price To Book
Scopus Biopharma fundamentals help investors to digest information that contributes to Scopus Biopharma's financial success or failures. It also enables traders to predict the movement of Scopus OTC Stock. The fundamental analysis module provides a way to measure Scopus Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Scopus Biopharma otc stock.
Scopus |
Scopus Biopharma OTC Stock Price To Book Analysis
Scopus Biopharma's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Current Scopus Biopharma Price To Book | 2.42 X |
Most of Scopus Biopharma's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Scopus Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
CompetitionBased on the latest financial disclosure, Scopus Biopharma has a Price To Book of 2.4153 times. This is 90.59% lower than that of the Healthcare sector and 60.01% lower than that of the Biotechnology industry. The price to book for all United States stocks is 74.6% higher than that of the company.
Scopus Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Scopus Biopharma's direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Scopus Biopharma could also be used in its relative valuation, which is a method of valuing Scopus Biopharma by comparing valuation metrics of similar companies.Scopus Biopharma is currently under evaluation in price to book category among its peers.
Scopus Fundamentals
| Return On Equity | -15.6 | ||||
| Return On Asset | -4.61 | ||||
| Current Valuation | 1.18 M | ||||
| Shares Outstanding | 21.09 M | ||||
| Shares Owned By Insiders | 50.66 % | ||||
| Shares Owned By Institutions | 2.15 % | ||||
| Number Of Shares Shorted | 23.77 K | ||||
| Price To Book | 2.42 X | ||||
| EBITDA | (26.18 M) | ||||
| Net Income | (26.95 M) | ||||
| Cash And Equivalents | 1.16 M | ||||
| Cash Per Share | 0.05 X | ||||
| Total Debt | 2.54 M | ||||
| Debt To Equity | 0.61 % | ||||
| Current Ratio | 0.31 X | ||||
| Book Value Per Share | (0.26) X | ||||
| Cash Flow From Operations | (11.42 M) | ||||
| Short Ratio | 0.22 X | ||||
| Earnings Per Share | (1.51) X | ||||
| Target Price | 12.0 | ||||
| Beta | 1.16 | ||||
| Market Capitalization | 2.17 M | ||||
| Total Asset | 8.19 M | ||||
| Z Score | -9.9 | ||||
| Net Asset | 8.19 M |
Thematic Opportunities
Explore Investment Opportunities
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Scopus OTC Stock
If you are still planning to invest in Scopus Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Scopus Biopharma's history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |